Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SC0032 is an investigational oral spray developed by Sensory Cloud for the treatment of refractory chronic cough (RCC) and unexplained chronic cough (UCC). The therapeutic is based on a proprietary salt-based platform designed to stabilize the airway lining fluid (ALF). By delivering a specific ionic formulation (typically involving calcium and sodium salts) to the upper airways, SC0032 aims to enhance the physical integrity of the ALF, thereby reducing the hypersensitivity of airway nerves and suppressing the cough reflex. This mechanism differs from traditional antitussives by targeting the physical environment of the airway rather than specific neural receptors. It is currently being evaluated in Phase II clinical trials to assess its efficacy in reducing cough frequency and improving patient-reported outcomes.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on SC0032.